Compare Emerson Electric Co. (EMR) vs McKesson Corporation (MCK) Price & Performance

Emerson Electric (EMR) trades at $137.06, up 0.7% on the day, with a bearish technical signal but strong analyst support. Recent earnings have mostly beaten expectations, with Q2 2026 results pending. The company maintains solid profitability with a 13.35% net income margin and a consensus price target of $157.60, suggesting 15% upside. Cash flow trends show operational strength despite net outflows, and a dividend of $0.56 was recently declared.

EMR presents a mixed outlook: bullish fundamentals and analyst ratings contrast with near-term technical weakness. Investment appeal hinges on earnings execution and sector momentum, while risks include debt levels and market volatility. The stock's valuation at a P/E of 31.54 requires sustained growth to justify further gains.

MCK trades at $836.49, up 4.12% in the last session, with a neutral technical signal and strong analyst consensus. Recent earnings consistently beat expectations, with Q1 2026 EPS of $11.69 surpassing the $11.56 estimate. Revenue growth is robust, reaching $359.05B in 2025, though net margins remain thin at 1.18%. The stock is supported by positive cash flow trends and a dividend payout scheduled for July 2026.

The outlook is positive, driven by earnings momentum and a $932.83 consensus price target implying 11.5% upside. Risks include low profitability margins and high liabilities, but institutional sentiment is bullish with 80% buy ratings. Investors should weigh growth in specialty pharma against execution and regulatory pressures in the healthcare sector.